Compound LM9, a novel MyD88 inhibitor, efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy

Mechanisms of cardiomyopathy caused by obesity/hyperlipidemia are complicated. Obesity is usually associated with chronic low-grade inflammation and may lead to the onset and progression of myocardial fibrosis and remodeling. TLR4/MyD88 signaling pathway, as a key regulator of inflammation, plays an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xu-yong, Sun, Chu-chu, Liu, Qian, Lu, Xiao-yao, Fu, Li-li, Liang, Guang, Zhang, Xiu-hua, Chen, Gao-zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468329/
https://www.ncbi.nlm.nih.gov/pubmed/32341464
http://dx.doi.org/10.1038/s41401-020-0410-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468329/
https://www.ncbi.nlm.nih.gov/pubmed/32341464
http://dx.doi.org/10.1038/s41401-020-0410-x

Ejemplares similares